←
Nicholas Short MD351 posts
Nicholas Short MD avatar

Nicholas Short MD

@NicholasShortMD

Associate Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays

◷ Joined February 2017▧ 8 Photos and videos
Keith W Pratz MD avatar
⟳ Nicholas Short MD retweeted
Keith W Pratz MD@PratzKW·Aug 28

My commentary on the LTFU data from Short et al in Blood Advances with the addition of Gilteritinib to Azacitidine and Venetoclax for FLT3 mutant AML. Encouraging OS(29.7m) but myelosuppression in older adult(71 YO median) population remains a challenge. ashpublications.org/bloodadv…

Walid Macaron, MD MSc avatar
⟳ Nicholas Short MD retweeted
Walid Macaron, MD MSc@WNMacaron·May 25

Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras. Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.

Post attachmentPost attachment
Nicholas Short MD avatar
Nicholas Short MD@NicholasShortMD·27 Dec 2024

Very nice of @AjHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: onlinelibrary.wiley.com/doi/… @DillonHaem

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology doi.org/10.1002/ajh.27482 #leusm

Post attachment
ALL Hub avatar
⟳ Nicholas Short MD retweeted
ALL Hub@ALL_Hub_·9 Dec 2024

CONGRESS #ASH24 | PRESENTATION @WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: lymphoblastic-hub.com/medica… #ALL #ALLsm

Post attachmentPost attachmentPost attachmentPost attachment
ALL Hub avatar
⟳ Nicholas Short MD retweeted
ALL Hub@ALL_Hub_·9 Dec 2024

CONGRESS #ASH24 | PRESENTATION Roberta Santos Azevedo, @MDAndersonNews discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest in pts over 60 with TP53 mutation, with a 5-yr CI of 25% Follow our live feed for more updates: lymphoblastic-hub.com/medica… #ALL #ALLsm

Post attachmentPost attachmentPost attachmentPost attachment